March 8, 2021
The Pharmaceuticals and Medical Devices Agency (PMDA) is investigating a new side effect risk for three drugs including AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab), a move likely to trigger label changes in the near future. According to the agency’s risk communication...read more